Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies
Authors' conclusion
More than 4 out of 5 patients with T2D had a CV or kidney indication for either SGLT2i or GLP-1 RA. However, uptake of SGLT2i/GLP-1 RA in these high-risk populations remains low (just 32%) across this health network. Future studies are needed to identify better strategies to overcome provider, patient, and system-level barriers to the uptake and dissemination of guideline-concordant T2D therapies.
Study context
- Population
- Patients 18 years of age or older with T2D and at least 1 hemoglobin A1c (HbA1c) between January 1, 2020 and January 1, 2023patients who met inclusion criteria
- Participants
- 147,338 patients
- Outcome
- Indication for either SGLT2i or GLP-1 RA based on guideline recommendations
Methodological detailslarge health network in the Northeastern United States
- Large health network in the Northeastern United States
Main finding
As reported in the abstract
Patients with an indication
121,508
83%
Further findings
Prescription of SGLT2i and/or GLP-1 RA among patients with an indication
- Prescribed an SGLT2i
- 17%
- Prescribed GLP-1 RA
- 22%
- Prescribed both medications
- 6%
- All eligible patients prescribed therapy
- 33%
Indications among eligible patients not currently receiving either therapy
- 10-year atherosclerotic CV disease (ASCVD) risk ≥ 10% without known ASCVD
- 49%
- ASCVD
- 42%
- Chronic kidney disease (CKD)
- 52%
- Heart failure (HF)
- 14%
Demographics of included patients
- Female
- 47%
- Non-white
- 28%
- Non-English language preference
- 14%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →